Clinical Trial Update: Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating GX-I7 in combination with pembrolizumab for refractory or relapsed triple negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• GX-I7
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genexine, Inc. | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED